'''Darglitazone''' (previously known as '''CP 86325-2''') is a member of the {{w|thiazolidinedione}} class of drugs and an agonist of [[Peroxisome proliferator-activated receptor gamma|peroxisome proliferator-activated receptor-γ]] (PPAR-γ), an orphan member of the nuclear receptor superfamily of transcription factors. It has a variety of insulin-sensitizing effects, such as improving glycemic and lipidemic control, and was researched by [[Pfizer]] as a treatment of metabolic disorders such as {{w|Diabetes mellitus type 2|type 2 diabetes mellitus}}.<ref>{{Cite journal|doi=10.1021/jm00088a022|title=Novel thiazolidine-2,4-diones as potent euglycemic agents|pmid=1588563|year=1992|last1=Hulin|first1=Bernard|last2=Clark|first2=David A.|last3=Goldstein|first3=Steven W.|last4=McDermott|first4=Ruth E.|last5=Dambek|first5=Paul J.|last6=Kappeler|first6=Werner H.|last7=Lamphere|first7=Charles H.|last8=Lewis|first8=Diana M.|last9=Rizzi|first9=James P.|journal=Journal of Medicinal Chemistry|volume=35|issue=10|pages=1853–64}}</ref>
